Carsgen announces positive topline results from china gc/gej pivotal phase ii clinical trial of claudin18.2 car-t (satri-cel)

Shanghai , dec. 30, 2024 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal phase ii clinical trial ct041-st-01(nct04581473). this study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel ("satri-cel", ct041) (an autologous car t-cell product candidate against claudin18.2) in subjects with claudin18.2 expression-positive, advanced gastric/gastroesophageal junction cancers that have failed at least 2 prior lines therapy.
CAR Ratings Summary
CAR Quant Ranking